IVD China last week: Autobio, Wondfo, Dirui and BGI

Autobio Invests in a Pan-Cancer Screening IVD Company

Autobio has made a new external investment in Renke (Beijing) Biotech Co., Ltd., subscribing to CNY 400,000 of new equity, accounting for 9.09% of Renke Biotech's total share capital. Established in 2021, Renke Biotech is a developer of cancer chromatin testing technology, aiming to address industry pain points and build a big data platform for blood health. The company has independently developed a single-cell ATAC-seq technology, constructing a pan-cancer chromatin accessibility database at the single-cell level, significantly improving the accuracy of cancer type tracing. This technology is expected to be applicable for early screening of all cancer types.

Wondfo Biotech Cooperates with Universiti Sains Malaysia

Wondfo Biotech has officially signed an agreement with Universiti Sains Malaysia (USM), a top university ranked in the top 1% globally. The two parties will strengthen cooperation in deepening academic exchanges and accelerating the transformation of scientific research achievements. Based in China and serving globally, Wondfo Biotech continues to promote industry-university-research cooperation worldwide, driving innovation and application in the medical testing field, contributing to global healthcare. As early as 2022, Wondfo Biotech began research cooperation with USM on the severe application of POCT. The signing of this agreement will further deepen the industry-university-research cooperation between the two parties. According to the agreement, Wondfo Biotech and USM will strengthen academic exchanges, cooperate in clinical research, jointly develop products, and promote scientific innovation and application in the medical testing field for the greater benefit of human health.

Dirui Industrial Officially Becomes an IFCC Member

Dirui Industrial Co., Ltd., one of the leading enterprises in China's in vitro diagnostics industry, has officially become a member unit of The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Dirui will continue to improve testing efficiency and accuracy through continuous independent innovation, providing advanced solutions to meet the ever-changing technological needs of global diagnostic laboratories. By leveraging the global diagnostic development exchange platform, Dirui aims to fulfill its corporate mission of "Leading Diagnostic Science, Safeguarding Public Health" and engage in more experience exchange and sharing with global experts in clinical chemistry and laboratory medicine.

BGI Collaborates with Uppsala University in Sweden to Publish the World's Largest Multimodal Study on Colorectal Cancer

Uppsala University in Sweden, in collaboration with BGI Research, BGI Genomics Intelligent Healthcare Institute, and based on the BGI Genomics DNBSEQ sequencing platform, conducted whole-genome and transcriptome sequencing analysis on 1,063 colorectal cancer samples. The study identified a series of genes related to different stages of cancer and identified key prognostic factors for colorectal cancer, providing a data foundation for the prevention, treatment, and prognosis of colorectal cancer. The related research was published on August 7th in the globally renowned academic journal Nature. It is worth mentioning that this is also the world's largest multimodal study on colorectal cancer to date.